Brazil’s ANVISA and ProGenericos sign cooperation agreement
Brazil's National Health Surveillance Agency, ANVISA has signed a memorandum of technical and operational cooperation with the Brazilian Association of Manufacturers of Generic Drugs (ProGenericos) which provides for study, research, information sharing, planning and common interest projects planning, writes Juliane Carvalho of Brazil Pharma News.
The agreement also includes actions taken within the health policy, science and technology as well as supporting the development of generic medicines and biological drugs. The ceremony took place at the 6th Meeting of the Executive Committee and Competitiveness Council of Health Complex (GECIS) in Brasilia.
The Generic Drug Policy was introduced in Brazil by Law No 9,787, of February 10, 1999, as a strategy to promote access to medicines, as these products are lower cost to the population.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biosimilars
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze